Biosimilars and Oncology Clinical Pathways: Perfect Together

BiosimilarsПодробнее

The Complexity of Choosing Biosimilars in OncologyПодробнее

Biosimilars in Oncology: Future DirectionsПодробнее

Dr. Tripathy on the Progression of Biosimilars in OncologyПодробнее

Impact of Biosimilars on the Field of OncologyПодробнее

The potential of biosimilars in cancer treatmentПодробнее

Dr. Slamon Discusses the Future of Biosimilars in OncologyПодробнее

What is Needed and What is the Role of Biosimilars?Подробнее

Dr. Hurvitz on the Clinical Use of Biosimilars in OncologyПодробнее

Dr. Schmid on Challenges Concerning Biosimilars in OncologyПодробнее

Dr. Ali on Whether Biosimilars Can Replace Biologics in OncologyПодробнее

Practical Considerations in Integrating HER2 Biosimilars in Clinical PracticeПодробнее

Dr. Markman on the Concept of Biosimilars in OncologyПодробнее

Biosimilars in Oncology: Addressing AwarenessПодробнее

Biosimilars for breast cancer treatmentПодробнее

Dr Ali McBride Discusses the Role of Biosimilars in OncologyПодробнее

Dr. Kwa on the Potential Impact of Biosimilars in OncologyПодробнее

Biosimilars Part 1: History and BiologyПодробнее

Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptinПодробнее